AnaptysBio director Renton sells 5,000 shares

Q: How many ANAB shares did director Hollings Renton sell, and at what price?

Hollings Renton sold 5,000 shares on October 1, 2026, at a weighted average price of $49.8743 per share. The shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, under a Rule 10b5-1 plan adopted March 30, 2026.

Q: What options did Hollings Renton hold after the ANAB transaction?

Renton also held remaining options to purchase 10,000 common shares and additional options to purchase up to an aggregate of 92,320 common shares; the additional options vest according to their terms.

The director’s sale was made under a Rule 10b5-1 plan adopted March 30, 2026; the exercised option was fully vested and exercisable.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AnaptysBio, Inc. director Hollings Renton exercised a fully vested and exercisable option to acquire 5,000 common shares at an exercise price of $18.03 per share on October 1, 2026, then sold 5,000 shares that day at a weighted average of $49.8743 per share.

The sale was made under a Rule 10b5-1 trading plan adopted March 30, 2026. Sale prices ranged from $49.435 to $50.37 per share.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($159K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider RENTON HOLLINGS

Role Director

Sold 5,000 shs ($249K)

Approx. gross sale proceeds $249K

Approx. exercise cost $90K

Approx. pre-tax spread $159K

Type	Security	Shares	Price	Value
Exercise	Common Stock ^{F3, F4}	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$18.03	$90K
Sale	Common Stock ^{F1, F2}	5,000	$49.8743	$249K

Holdings After Transaction: Common Stock — 10,000 contracts (Direct); Common Stock — 10,995 shares (Direct)

Footnotes (4)

F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The stock option is fully vested and exercisable.
F4. In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.

Key Figures

Shares acquired through option exercise: 5,000 shares Option exercise price: $18.03 per share Shares sold: 5,000 shares +4 more

7 metrics

Shares acquired through option exercise 5,000 shares October 1, 2026

Option exercise price $18.03 per share Exercise of 5,000 options on October 1, 2026

Shares sold 5,000 shares October 1, 2026

Weighted average sale price $49.8743 per share Sale on October 1, 2026

Sale price range $49.435 to $50.37 per share Multiple transactions on October 1, 2026

Remaining options to purchase 10,000 shares Common shares

Additional options to purchase Up to an aggregate of 92,320 shares Common shares; options vest according to their terms

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANAB shares did director Hollings Renton sell, and at what price?

Hollings Renton sold 5,000 shares on October 1, 2026, at a weighted average price of $49.8743 per share. The shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, under a Rule 10b5-1 plan adopted March 30, 2026.

What options did Hollings Renton hold after the ANAB transaction?

Renton also held remaining options to purchase 10,000 common shares and additional options to purchase up to an aggregate of 92,320 common shares; the additional options vest according to their terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 05:48 PM Accepted by SEC EDGAR 10/02/2026 - 05:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RENTON HOLLINGS

(Last)

(First)

(Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		5,000	A	$18.03	15,995	D
Common Stock	10/01/2026		S⁽¹⁾		5,000	D	$49.8743⁽²⁾	10,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	$18.03	10/01/2026		M			5,000	⁽³⁾	02/23/2027	Common Stock	5,000	$0	10,000⁽⁴⁾	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The stock option is fully vested and exercisable.

4. In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.

	/s/ Christopher Murphy, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR